Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Companies

Set Alert for Companies

Boston Scientific Puts Charge In Neuromodulation Business By Acquiring Relievant

Relievant’s Intracept intraosseous nerve ablation system is the only FDA-cleared neuromodulation device indicated to treat vertebrogenic pain. Boston Scientific will pay $850m for Relievant, plus undisclosed milestone payments over the next three years.

M & A Neurology

Medtech DEI Experts Talk Shop: ‘It’s Going To Transform Businesses’

An all-female panel of medtech DEI leaders at the LSX Congress USA conference discussed the importance of diversity and inclusion in research, clinical trials, product development and services to advance health equity as well as fundamental business goals.

Diversity & Inclusion Business Strategies

Federal Court Rejects Motion To Dismiss Case In Genomics Patent Infringement Suit

Parse Biosciences’ motion to dismiss a patent infringement case has been rejected by a US District Court.

Legal Issues Intellectual Property

FDA Updates Breakthrough Devices Guidance To Improve Health Equity

The US FDA has updated its final guidance to clarify use of the Breakthrough Devices Program in advancing health equity. The voluntary program was created to speed up the process of getting innovative medical devices to patients that treat life-threatening or debilitating diseases.

FDA Policy

PTAB Affirms Previous Decision In Favor Of Apple In Masimo Patent Case

A new decision from the PTAB upholds prior rulings rejecting four of Masimo’s appeals and reverses a decision on one.

Regulation Legal Issues

FDA Issues Three Draft Guidance Documents In Ongoing Effort To Improve 510(k) Submissions

As part of its ongoing effort to modernize its premarket notification 510(k) program, the US FDA has issued three draft guidance documents it says will improve the safety of critical medical devices and strengthen the submission process.

FDA Policy

Minute Insight: Illumina Seeks Stability, Names Thaysen As New CEO

The genome-sequencing giant has named Jacob Thaysen, who brings extensive experience from Agilent, as its new leader.

Minute Insights Executive Changes

Abbott Buys Bigfoot Biomedical – But What Lurks In The Forest?

Abbott and Bigfoot Biomedical have worked as partners for more than half a decade but will now continue as one. Analysts are questioning whether the merger will simply be a tuck-in for Abbott, or enable it to release an insulin pump of their own.

M & A Diabetic Care

Cardio Catch-Up: Advisory Panel Gives Recor Momentum Toward US Launch Of RDN System

The majority of FDA’s circulatory systems devices panel agreed that ReCor’s Paradise ultrasound renal denervation system offers a safe and effective therapy for patients with hypertension. The panel’s endorsement means ReCor will likely be the first company to reach the US market with an RDN system.

Advisory Committees Clinical Trials

Medtronic HVAD Woes Continue

Medtronic has identified additional HeartWare Ventricular Assist Device pumps that the company says have a higher risk of failure than average for the devices.

FDA Cardiology

RedDress Chronic Wound Treatment Wins Medicare Coverage

The ActiGraft PRO treatment for diabetic ulcers recently procured Medicare coverage nationwide, despite anti-abuse policies that have made reimbursement for new wound care products rare. Company general manager Robert Mueller talked about the process.

Medicare Policy

Danaher To Acquire Abcam For About $5.7Bn, Expand Services For Life-Science Industry

After a summer of speculation about who will close the deal with Abcam, tech leader Danaher came out ahead and will acquire Abcam for $24 a share.

M & A In Vitro Diagnostics

FTC Health Breach Proposal Could Create Confusion For HIPAA Entities

Medtech Insight followed up with Invitae’s Deven McGraw about further possible confusion that could be caused by the Federal Trade Commission’s proposed amendments to the Health Breach Notification Requirements (HBNR).

Policy Safety

FDA Sends Warning Letter To Integra Following Recall Of Surgical Repair Products

After an inspection of its Boston facility, the US FDA issued a warning letter to Integra LifeSciences' subsidiary TEI Biosciences for distributing collagen-based medical devices that failed bacterial endotoxin tests and did not conform to good manufacturing practices.

FDA Warning Letters

Death, Injuries Linked To Recalled Philips Ventilators

Philips recalled thousands of Trilogy Evo ventilators in March. The US FDA has designated the recall class I, its most serious type. 

FDA Regulation

Discard Diagnostics From Universal Meditech, FDA Warns

The US Food and Drug Administration is warning consumers not to use more than a dozen diagnostics from Universal Meditech, including pregnancy tests and those to detect urinary tract infections.

FDA Diagnostics
See All
UsernamePublicRestriction

Register